Hematopoietic stem cell transplantation for people with sickle cell disease

Chioma Oringanje, Eneida Nemecek, Oluseyi Oniyangi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Sickle cell disease is a genetic disorder involving a defect in the red blood cells due to its sickled hemoglobin. The main therapeutic interventions include preventive and supportive measures. Hematopoietic stem cell transplantations are carried out with the aim of replacing the defective cells and their progenitors (hematopoietic (i.e. blood forming) stem cells) in order to correct the disorder. This is an update of a previously published review. Objectives: To determine whether stem cell transplantation can improve survival and prevent symptoms and complications associated with sickle cell disease. To examine the risks of stem cell transplantation against the potential long-term gain for people with sickle cell disease. Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Group's Haemoglobinopathies Trials Register complied from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of The Cochrane Library) and quarterly searches of MEDLINE. Unpublished work was identified by searching the abstract books of major conference proceedings and we conducted a search of the website: www.ClinicalTrials.gov. Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 06 October 2015. Selection criteria: Randomized controlled and quasi-randomized studies that compared any method of stem cell transplantation with either each other or with any of the preventive or supportive interventions (e.g. periodic blood transfusion, use of hydroxyurea, antibiotics, pain relievers, supplemental oxygen) in people with sickle cell disease irrespective of the type of sickle cell disease, gender and setting. Data collection and analysis: No relevant trials were identified. Main results: Ten trials were identified by the initial search and none for the update. None of these trials were suitable for inclusion in this review. Authors' conclusions: Reports on the use of hematopoietic stem cell transplantation improving survival and preventing symptoms and complications associated with sickle cell disease are currently limited to observational and other less robust studies. No randomized controlled trial assessing the benefit or risk of hematopoietic stem cell transplantations was found. Thus, this systematic review identifies the need for a multicentre randomized controlled trial assessing the benefits and possible risks of hematopoietic stem cell transplantations comparing sickle status and severity of disease in people with sickle cell disease.

Original languageEnglish (US)
Article numberCD007001
JournalCochrane Database of Systematic Reviews
Volume2016
Issue number5
DOIs
StatePublished - May 19 2016

Fingerprint

Hematopoietic Stem Cell Transplantation
Sickle Cell Anemia
Stem Cell Transplantation
Hemoglobinopathies
Inborn Genetic Diseases
Randomized Controlled Trials
Hydroxyurea
Hematopoietic Stem Cells
Cystic Fibrosis
MEDLINE
Blood Transfusion
Patient Selection
Libraries
Hemoglobins
Stem Cells
Erythrocytes
Oxygen
Anti-Bacterial Agents
Pain

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Hematopoietic stem cell transplantation for people with sickle cell disease. / Oringanje, Chioma; Nemecek, Eneida; Oniyangi, Oluseyi.

In: Cochrane Database of Systematic Reviews, Vol. 2016, No. 5, CD007001, 19.05.2016.

Research output: Contribution to journalArticle

@article{31cdfd2c5e9e433ab684ed155771919f,
title = "Hematopoietic stem cell transplantation for people with sickle cell disease",
abstract = "Background: Sickle cell disease is a genetic disorder involving a defect in the red blood cells due to its sickled hemoglobin. The main therapeutic interventions include preventive and supportive measures. Hematopoietic stem cell transplantations are carried out with the aim of replacing the defective cells and their progenitors (hematopoietic (i.e. blood forming) stem cells) in order to correct the disorder. This is an update of a previously published review. Objectives: To determine whether stem cell transplantation can improve survival and prevent symptoms and complications associated with sickle cell disease. To examine the risks of stem cell transplantation against the potential long-term gain for people with sickle cell disease. Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Group's Haemoglobinopathies Trials Register complied from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of The Cochrane Library) and quarterly searches of MEDLINE. Unpublished work was identified by searching the abstract books of major conference proceedings and we conducted a search of the website: www.ClinicalTrials.gov. Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 06 October 2015. Selection criteria: Randomized controlled and quasi-randomized studies that compared any method of stem cell transplantation with either each other or with any of the preventive or supportive interventions (e.g. periodic blood transfusion, use of hydroxyurea, antibiotics, pain relievers, supplemental oxygen) in people with sickle cell disease irrespective of the type of sickle cell disease, gender and setting. Data collection and analysis: No relevant trials were identified. Main results: Ten trials were identified by the initial search and none for the update. None of these trials were suitable for inclusion in this review. Authors' conclusions: Reports on the use of hematopoietic stem cell transplantation improving survival and preventing symptoms and complications associated with sickle cell disease are currently limited to observational and other less robust studies. No randomized controlled trial assessing the benefit or risk of hematopoietic stem cell transplantations was found. Thus, this systematic review identifies the need for a multicentre randomized controlled trial assessing the benefits and possible risks of hematopoietic stem cell transplantations comparing sickle status and severity of disease in people with sickle cell disease.",
author = "Chioma Oringanje and Eneida Nemecek and Oluseyi Oniyangi",
year = "2016",
month = "5",
day = "19",
doi = "10.1002/14651858.CD007001.pub4",
language = "English (US)",
volume = "2016",
journal = "The Cochrane database of systematic reviews",
issn = "1361-6137",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation for people with sickle cell disease

AU - Oringanje, Chioma

AU - Nemecek, Eneida

AU - Oniyangi, Oluseyi

PY - 2016/5/19

Y1 - 2016/5/19

N2 - Background: Sickle cell disease is a genetic disorder involving a defect in the red blood cells due to its sickled hemoglobin. The main therapeutic interventions include preventive and supportive measures. Hematopoietic stem cell transplantations are carried out with the aim of replacing the defective cells and their progenitors (hematopoietic (i.e. blood forming) stem cells) in order to correct the disorder. This is an update of a previously published review. Objectives: To determine whether stem cell transplantation can improve survival and prevent symptoms and complications associated with sickle cell disease. To examine the risks of stem cell transplantation against the potential long-term gain for people with sickle cell disease. Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Group's Haemoglobinopathies Trials Register complied from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of The Cochrane Library) and quarterly searches of MEDLINE. Unpublished work was identified by searching the abstract books of major conference proceedings and we conducted a search of the website: www.ClinicalTrials.gov. Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 06 October 2015. Selection criteria: Randomized controlled and quasi-randomized studies that compared any method of stem cell transplantation with either each other or with any of the preventive or supportive interventions (e.g. periodic blood transfusion, use of hydroxyurea, antibiotics, pain relievers, supplemental oxygen) in people with sickle cell disease irrespective of the type of sickle cell disease, gender and setting. Data collection and analysis: No relevant trials were identified. Main results: Ten trials were identified by the initial search and none for the update. None of these trials were suitable for inclusion in this review. Authors' conclusions: Reports on the use of hematopoietic stem cell transplantation improving survival and preventing symptoms and complications associated with sickle cell disease are currently limited to observational and other less robust studies. No randomized controlled trial assessing the benefit or risk of hematopoietic stem cell transplantations was found. Thus, this systematic review identifies the need for a multicentre randomized controlled trial assessing the benefits and possible risks of hematopoietic stem cell transplantations comparing sickle status and severity of disease in people with sickle cell disease.

AB - Background: Sickle cell disease is a genetic disorder involving a defect in the red blood cells due to its sickled hemoglobin. The main therapeutic interventions include preventive and supportive measures. Hematopoietic stem cell transplantations are carried out with the aim of replacing the defective cells and their progenitors (hematopoietic (i.e. blood forming) stem cells) in order to correct the disorder. This is an update of a previously published review. Objectives: To determine whether stem cell transplantation can improve survival and prevent symptoms and complications associated with sickle cell disease. To examine the risks of stem cell transplantation against the potential long-term gain for people with sickle cell disease. Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Group's Haemoglobinopathies Trials Register complied from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of The Cochrane Library) and quarterly searches of MEDLINE. Unpublished work was identified by searching the abstract books of major conference proceedings and we conducted a search of the website: www.ClinicalTrials.gov. Date of the most recent search of the Group's Haemoglobinopathies Trials Register: 06 October 2015. Selection criteria: Randomized controlled and quasi-randomized studies that compared any method of stem cell transplantation with either each other or with any of the preventive or supportive interventions (e.g. periodic blood transfusion, use of hydroxyurea, antibiotics, pain relievers, supplemental oxygen) in people with sickle cell disease irrespective of the type of sickle cell disease, gender and setting. Data collection and analysis: No relevant trials were identified. Main results: Ten trials were identified by the initial search and none for the update. None of these trials were suitable for inclusion in this review. Authors' conclusions: Reports on the use of hematopoietic stem cell transplantation improving survival and preventing symptoms and complications associated with sickle cell disease are currently limited to observational and other less robust studies. No randomized controlled trial assessing the benefit or risk of hematopoietic stem cell transplantations was found. Thus, this systematic review identifies the need for a multicentre randomized controlled trial assessing the benefits and possible risks of hematopoietic stem cell transplantations comparing sickle status and severity of disease in people with sickle cell disease.

UR - http://www.scopus.com/inward/record.url?scp=84969543342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969543342&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD007001.pub4

DO - 10.1002/14651858.CD007001.pub4

M3 - Article

C2 - 27194464

AN - SCOPUS:84969543342

VL - 2016

JO - The Cochrane database of systematic reviews

JF - The Cochrane database of systematic reviews

SN - 1361-6137

IS - 5

M1 - CD007001

ER -